Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-04-21

Clinical Trial Update: Alefacept for Prevention of Graft Versus Host Disease (GVHD) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating alefacept to prevent graft-versus-host disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Amevive (alefacept)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Graft Versus Host Disease | Phase 3 | Status: TERMINATED